Literature DB >> 18821941

Do cytokines have any role in Wilson's disease?

M K Goyal1, S Sinha, S A Patil, V Jayalekshmy, A B Taly.   

Abstract

The aim of this study was to determine the serum cytokine levels in patients with Wilson's disease (WD) and correlate with phenotype, therapeutic status and laboratory data. In this cross-sectional study, the serum levels of cytokines were estimated in 34 patients (M : F, 23 : 11; drug-naive, 11) with WD (mean age: 13.8 +/- 8.6 and 19.6 +/- 9.03 years) and compared with 30 controls. The following serum cytokines were analysed using enzyme-linked immunosorbent assay: (i) tumour necrosis factor (TNF)-alpha, (ii) interferon (IFN)-gamma, (iii) interleukin (IL)-2, (iv) IL-6 and (v) IL-4. Serum TNF-alpha (P < 0.001), IFN-gamma (P = 0.005) and IL-6 (P < 0.001) were detectable in WD compared with controls. However, serum level elevation of IL-4 (P = 0.49) and IL-2 (P = 0.11), although detectable compared with controls, was statistically insignificant. The disease severity and therapeutic status did not affect the cytokines. Presence of anaemia, leucopenia, thrombocytopenia, pancytopenia and hepatic dysfunction did not influence cytokine levels. There was a significant negative correlation between IL-6 and ceruloplasmin (P = 0.04) and anti-inflammatory cytokines (IL-4) and copper level (P = 0.01). Serum cytokines, both proinflammatory and anti-inflammatory subtypes, were elevated significantly in patients with WD. Further studies would establish their role in its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18821941      PMCID: PMC2561097          DOI: 10.1111/j.1365-2249.2008.03755.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Copper induces the assembly of a multiprotein aggregate implicated in the release of fibroblast growth factor 1 in response to stress.

Authors:  M Landriscina; C Bagalá; A Mandinova; R Soldi; I Micucci; S Bellum; I Prudovsky; T Maciag
Journal:  J Biol Chem       Date:  2001-05-10       Impact factor: 5.157

2.  Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor.

Authors:  T Watanabe; M Seno; R Sasada; K Igarashi
Journal:  Mol Endocrinol       Date:  1990-06

3.  Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor.

Authors:  S S Brem; D Zagzag; A M Tsanaclis; S Gately; M P Elkouby; S E Brien
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

Review 4.  Trace elements in human physiology and pathology. Copper.

Authors:  H Tapiero; D M Townsend; K D Tew
Journal:  Biomed Pharmacother       Date:  2003-11       Impact factor: 6.529

5.  Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis.

Authors:  Ming Song; Zhenyuan Song; Shirish Barve; Jingwen Zhang; Theresa Chen; Marcia Liu; Gavin E Arteel; George J Brewer; Craig J McClain
Journal:  J Pharmacol Exp Ther       Date:  2008-02-25       Impact factor: 4.030

6.  Autonomic dysfunction in Wilson's disease --a clinical and electrophysiological study.

Authors:  Salvadeeswaran Meenakshi-Sundaram; Arun B Taly; Vikram Kamath; G R Arunodaya; Shivaji Rao; H S Swamy
Journal:  Clin Auton Res       Date:  2002-06       Impact factor: 4.435

Review 7.  The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease.

Authors:  V Hugh Perry
Journal:  Brain Behav Immun       Date:  2004-09       Impact factor: 7.217

Review 8.  Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.

Authors:  G J Brewer
Journal:  J Cell Mol Med       Date:  2003 Jan-Mar       Impact factor: 5.310

9.  Role of prostaglandin E1 and copper in angiogenesis.

Authors:  M Ziche; J Jones; P M Gullino
Journal:  J Natl Cancer Inst       Date:  1982-08       Impact factor: 13.506

10.  Sensory evoked potentials in Wilson's disease.

Authors:  N S Chu
Journal:  Brain       Date:  1986-06       Impact factor: 13.501

View more
  7 in total

1.  Movement Disorder in Wilson Disease: Correlation with MRI and Biomarkers of Cell Injury.

Authors:  Jayantee Kalita; Vijay Kumar; Usha K Misra; Sunil Kumar
Journal:  J Mol Neurosci       Date:  2020-07-13       Impact factor: 3.444

2.  Neuropsychiatric Manifestations of Wilson Disease: Correlation with MRI and Glutamate Excitotoxicity.

Authors:  Jayantee Kalita; Vijay Kumar; Vasudev Parashar; Usha K Misra
Journal:  Mol Neurobiol       Date:  2021-08-26       Impact factor: 5.590

3.  Case of Early-Onset Parkinson's Disease in a Heterozygous Mutation Carrier of the ATP7B Gene.

Authors:  Ekaterina Y Ilyechova; Irina V Miliukhina; Marina N Karpenko; Iurii A Orlov; Ludmila V Puchkova; Sergey A Samsonov
Journal:  J Pers Med       Date:  2019-08-17

4.  Wilson's Disease Update: An Indian Perspective.

Authors:  Niraj Kumar; L K Prashant; Vinay Goyal
Journal:  Ann Indian Acad Neurol       Date:  2021-10-14       Impact factor: 1.383

5.  Wilson's Disease Update: An Indian Perspective.

Authors:  Kalyan Bhattacharya; Bindu Thankappan
Journal:  Ann Indian Acad Neurol       Date:  2022-02-18       Impact factor: 1.383

6.  Autoantibodies in Wilson disease: Impact on clinical course.

Authors:  Magdalena Antczak-Kowalska; Anna Członkowska; Ceren Eyileten; Anna Palejko; Agnieszka Cudna; Marta Wolska; Agnieszka Piechal; Tomasz Litwin
Journal:  JIMD Rep       Date:  2022-07-22

7.  Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B(-/-) (Wilson disease) mice.

Authors:  James P Hamilton; Lahari Koganti; Abigael Muchenditsi; Venkata S Pendyala; David Huso; Joseph Hankin; Robert C Murphy; Dominik Huster; Uta Merle; Christopher Mangels; Nan Yang; James J Potter; Esteban Mezey; Svetlana Lutsenko
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.